advertisement
Abstract #47853 Published in IGR 13-4
Timogel((registered trademark)) vs timolol 0.5% ophthalmic solution: Efficacy, safety, and acceptance
Rolle T; Curto D; Alovisi C; Franzone M; Brogliatti B; Grignolo FMEuropean Journal of Ophthalmology 2011; 22: 28-33
Purpose. To evaluate the efficacy, safety, and tolerability of Timogel((registered trademark)) preservative-free once daily compared to timolol 0.5% ophthalmic solution bid in patients with ocular hypertension (OHT) and patients with primary open-angle glaucoma (POAG). methods. A total of 75 patients with OHT and patients with POAG treated with timolol 0.5% bid with intraocular pressure (IOP) (less-than or equal to)21 mmHg were enrolled. They underwent complete ophthalmologic examination, IOP measurements (at trough and daytime curve), evaluation of side effects, Schirmer test, break-up time [BUT], blood pressure, heart rate, ocular diastolic perfusion pressure measurements, and acceptance (Comparison of Ophthalmic Medications for Tolerability). Patients switched to Timo-gel((registered trademark)) and were re-evaluated 3 months later. The analysis of variance and the Pearson (chi)(2) tests were used to test differences between the treatments results. Intraocular pressure reduction at trough was 23.6% with timolol 0.5% and 22.3% with Ti-mogel((registered trademark)). No statistical differences were observed in IOP values at trough and in the daytime curve between the 2 treatments. Local and systemic side effects were less frequent with Timogel((registered trademark)) (hazard ratio: p<0.05). Patients demonstrated a significant improvement of Schirmer test and BUT (p<0.05) and a reduction of dryness and foreign body sensation (42.6% vs 15.4%; p<0.01) after switching to Timogel((registered trademark)). Mild and short-lasting blurred vision after Timogel((registered trademark)) instillation occurred in about 18.5% of patients. A total of 82% of patients were satisfied or very satisfied with Timogel((registered trademark)) vs 61% with previous treatment (p<0.01). ConClusions. Timogel((registered trademark)) preservative-free dosed once every morning has a 24-hour hypotensive effect with a better safety profile than timolol 0.5% bid and it is well-accepted by patients. The once-daily dosing improved acceptance and compliance. (copyright) 2011 Wichtig Editore.
T. Rolle. Department of Clinical Physiopathology, Section of Ophthalmology, Eye Clinic, University of Torino, Via Juvarra 19, 10122 Torino, Italy. Email: teresa.rolle@unito.it
Classification:
11.16 Vehicles, delivery systems, pharmacokinetics, formulation (Part of: 11 Medical treatment)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
